GSK BLISSc-ILD 218224 Patient

This app has been created exclusively for participants in the medical study for GSK BLISSc-ILD. It contains Televisit functionality and allows participants to complete questionnaires. A Phase 2/3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with systemic sclerosis associated interstitial lung disease (SSc-ILD).